Insider Buying: Hims & Hers Health (NYSE:HIMS) Director Purchases 48,400 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director David Wells acquired 48,400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Hims & Hers Health Stock Up 0.2%

Shares of NYSE:HIMS traded up $0.04 during midday trading on Tuesday, reaching $23.79. 15,724,693 shares of the company were exchanged, compared to its average volume of 32,291,996. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock has a fifty day simple moving average of $24.03 and a two-hundred day simple moving average of $27.85. The firm has a market cap of $5.42 billion, a PE ratio of -264.33, a P/E/G ratio of 46.09 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health during the fourth quarter worth $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health during the third quarter worth $28,000. Bogart Wealth LLC grew its position in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Finally, Greenline Wealth Management LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $36,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on HIMS shares. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. TD Cowen reduced their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Truist Financial increased their price objective on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.70.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.